MedTrace Logo

Topical Steroids and Cyclosporin-A for COVID-19 Keratoconjunctivitis

NCT04451239 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-06-30

No results posted yet for this study

Summary

To explore the feasibility of combined topical corticosteroid and topical cyclosporine-A in COVID-19 patients with acute keratoconjunctivitis.

Conditions

  • Keratonjunctivitis

Interventions

DRUG

topical steroids and cyclosporin-A

All patient will be treated with Topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .

Sponsors & Collaborators

  • Ministry of Health, Kuwait

    collaborator OTHER_GOV

  • Ameera Gamal Abdelhameed

    lead OTHER

Principal Investigators

  • Mona Nasseif, MD · Tanta University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-30
Primary Completion
2020-07-31
Completion
2020-07-31

Countries

  • Kuwait

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04451239 on ClinicalTrials.gov